Technical Analysis for IMMP - Immutep Ltd ADR

Grade Last Price % Change Price Change
grade C 2.09 20.11% 0.3500
IMMP closed up 20.11 percent on Tuesday, January 21, 2020, on 2.88 times normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical IMMP trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New 52 Week High Strength 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
New 52 Week Closing High Bullish 20.11%
New 52 Week High Strength 20.11%
Up 3 Days in a Row Strength 20.11%
New 52 Week Closing High Bullish 30.63%
New 52 Week High Strength 30.63%
Older signals for IMMP ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti), an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer. Its other products include TACTI-002, a combination of efti with KEYTRUDA that is in a Phase II clinical trial for solid tumors; INSIGHT-004, a human anti-PD-L1 antibody, which is in a Phase I clinical trial to evaluate a combination of efti with avelumab; and TACTI-mel that is in a Phase I clinical trial for metastatic melanoma. The company also develops IMP761 for autoimmune disease. It has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreements with Merck KGaA, Darmstadt, Germany, and Pfizer Inc.; and partnerships with GlaxoSmithKline, Novartis, CYTLIMIC, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.
Biotechnology Cancer Clinical Medicine Drugs Treatment Of Cancer Solid Tumors Alpha Autoimmune Diseases Cancer Treatments Antineoplastic Drugs Biological Products Breakthrough Therapy Metastatic Melanoma Metastatic Breast Cancer Merck Autoimmune Disease Immunotherapeutic Products Immutep L1 Novartis Pembrolizumab Avelumab Eftilagimod Alpha Immunotherapeutic Lag3

Is IMMP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.25
52 Week Low 1.38
Average Volume 45,682
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.0000
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0000
MACD Signal Line 0.0000
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.3900
Resistance 3 (R3) 2.4100 2.3300 2.3400
Resistance 2 (R2) 2.3300 2.2536 2.3200 2.3233
Resistance 1 (R1) 2.2100 2.2064 2.1700 2.1900 2.3067
Pivot Point 2.1300 2.1300 2.1100 2.1200 2.1300
Support 1 (S1) 2.0100 2.0536 1.9700 1.9900 1.8733
Support 2 (S2) 1.9300 2.0064 1.9200 1.8567
Support 3 (S3) 1.8100 1.9300 1.8400
Support 4 (S4) 1.7900